Risk for Chronic Fatigue Syndrome Higher After COVID-19
THURSDAY, Jan. 16, 2025 -- The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to a study published online Jan. 13 in the Journal of General Internal Medicine.
Suzanne D. Vernon, Ph.D., from the Bateman Horne Center in Salt Lake City, and colleagues estimated the incidence and prevalence of post-COVID-19 ME/CFS among adults enrolled in the Researching COVID to Enhance Recovery study. The analysis included 4,515 acute infected, enrolled within 30 days of infection or enrolled as uninfected who became infected; 7,270 post-acute infected, enrolled >30 days after infection; and 1,439 uninfected participants.
The researchers found that the incidence rate of ME/CFS in participants followed from time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was 2.66 per 100 person-years compared with 0.93 per 100 person-years in matched uninfected participants (hazard ratio, 4.93). Overall, the proportion of participants who met criteria for ME/CFS following SARS-CoV-2 infection was 4.5 percent versus 0.6 percent in uninfected participants. The most common ME/CFS symptom in infected participants was post-exertional malaise (24.0 percent). Most post-COVID participants with ME/CFS also met criteria for long COVID (88.7 percent).
"These post-pandemic prevalence rates are in contrast to pre-pandemic ME/CFS prevalence estimates, which ranged from 0.2 to 1.0 percent of people in the United States and is in line with what we found in uninfected participants," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Further Support and Information on COVID-19
Read this next
Azelastine Nasal Spray Reduces Risk for SARS-CoV-2 Infection
FRIDAY, Sept. 5, 2025 -- Azelastine nasal spray is associated with a reduced risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study...
COVID-19 Tied to Higher Risk for Inflammatory Diseases of the Airways
THURSDAY, Aug. 28, 2025 -- People who have had COVID-19 have an increased risk for developing certain new-onset type 2 inflammatory diseases of the airways, while receipt of a...
COVID-19 Infection Linked to Accelerated Vascular Aging
MONDAY, Aug. 18, 2025 -- COVID-19 is associated with early vascular aging, as assessed by carotid-femoral pulse wave velocity (PWV), an established biomarker of large artery...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.